Plain-English translation of NCT07557225 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new diagnostic imaging scan called 18F-T2 PET/CT that may help doctors better detect and evaluate certain solid tumors. The scan uses a special tracer injected into your bloodstream that targets a specific protein called CAIX, which is found in high levels in many types of cancer. Researchers want to see how well this new imaging method works compared to standard scans, and whether it's safe and well-tolerated.
Current imaging scans don't always clearly show all tumors or help doctors understand them completely. This medication targets a protein that many solid tumors express, so it may help doctors detect cancer earlier and more accurately, and better plan treatment.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of the 18F-T2 tracer into your vein, followed by a PET/CT imaging scan to see how the tracer highlights your tumor. You would also have a standard PET/CT scan (using a different tracer) within one week. The study will monitor you for any side effects and measure the radiation dose you receive from these imaging procedures.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China